Literature DB >> 20850537

Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines.

Jane E Libbey1, Robert S Fujinami.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an experimental model for multiple sclerosis. EAE can be induced by inoculation with central nervous system (CNS) proteins or peptides emulsified in complete Freund's adjuvant. Protection from EAE, enhancement of EAE or subclinical priming for EAE can occur as a result of either live viral infection or DNA immunization with molecular mimics of CNS proteins or peptides. Here we review the published data describing modulation of EAE through administration of various CNS proteins/peptides introduced via live virus or plasmid DNA and modulation of EAE through choice of adjuvant (immunostimulating agents).
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20850537      PMCID： PMC3017664          DOI： 10.1016/j.vaccine.2010.08.103

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  61 in total

1.  The use of oil adjuvants in therapeutic vaccines.

Authors:  Jerome Aucouturier; Stephane Ascarateil; Laurent Dupuis
Journal:  Vaccine       Date:  2006-04-12       Impact factor: 3.641

2.  Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.

Authors:  Amanda L Gavin; Kasper Hoebe; Bao Duong; Takayuki Ota; Christopher Martin; Bruce Beutler; David Nemazee
Journal:  Science       Date:  2006-12-22       Impact factor: 47.728

Review 3.  Encephalitogenic epitopes of myelin basic protein.

Authors:  R B Fritz; D E McFarlin
Journal:  Chem Immunol       Date:  1989

4.  Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic relapsing-remitting experimental allergic encephalomyelitis.

Authors:  L Y Wang; D J Theil; J L Whitton; R S Fujinami
Journal:  J Neuroimmunol       Date:  1999-05-03       Impact factor: 3.478

Review 5.  Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis.

Authors:  Moses Rodriguez
Journal:  Brain Pathol       Date:  2007-04       Impact factor: 6.508

6.  Viruses can silently prime for and trigger central nervous system autoimmune disease.

Authors:  D J Theil; I Tsunoda; F Rodriguez; J L Whitton; R S Fujinami
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

Review 7.  Myelin sheaths and autoimmune response induced by myelin proteins and alphaviruses. I. Physicochemical background.

Authors:  Jan Sedzik
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 8.  Minireview: autoimmune responses to myelin proteolipid protein.

Authors:  R A Sobel; J M Greer; V K Kuchroo
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

Review 9.  Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review.

Authors:  V K Tuohy
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

10.  Private specificities of CD8 T cell responses control patterns of heterologous immunity.

Authors:  Sung-Kwon Kim; Markus Cornberg; Xiaoting Z Wang; Hong D Chen; Liisa K Selin; Raymond M Welsh
Journal:  J Exp Med       Date:  2005-02-14       Impact factor: 14.307
View more
  12 in total

1.  Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.

Authors:  Michael K Axthelm; Dennis N Bourdette; Gail H Marracci; Weiping Su; Elizabeth T Mullaney; Minsha Manoharan; Steven G Kohama; Jim Pollaro; Ellen Witkowski; Paul Wang; William D Rooney; Lawrence S Sherman; Scott W Wong
Journal:  Ann Neurol       Date:  2011-06-14       Impact factor: 10.422

Review 2.  Multiple sclerosis: autoimmunity and viruses.

Authors:  Matthew F Cusick; Jane E Libbey; Robert S Fujinami
Journal:  Curr Opin Rheumatol       Date:  2013-07       Impact factor: 5.006

Review 3.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis.

Authors:  Matthew F Cusick; Jane E Libbey; Luke Oh; Shaun Jordan; Robert S Fujinami
Journal:  Autoimmunity       Date:  2014-11-20       Impact factor: 2.815

5.  DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration.

Authors:  Jimmy Jianheng Zhou; Yuan Min Wang; Vincent Ws Lee; Richard Ks Phoon; Geoff Yu Zhang; Ya Wang; Thian Kui Tan; Min Hu; Lucy Dongwei Wang; Mitsuru Saito; Andrew Sawyer; David C H Harris; Stephen I Alexander; Anne M Durkan
Journal:  Int J Clin Exp Med       Date:  2012-01-15

Review 6.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

7.  Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.

Authors:  Matthew F Cusick; Jane E Libbey; Nikolaus S Trede; Robert S Fujinami
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

8.  A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model.

Authors:  Shuang Wang; Yang Yu; Shuang Geng; Dongmei Wang; Li Zhang; Xiaoping Xie; Bing Wu; Chaofan Li; Hanqian Xu; Xiaolin Li; Yanxin Hu; Lianfeng Zhang; Christoph Kaether; Bin Wang
Journal:  Alzheimers Res Ther       Date:  2014-05-12       Impact factor: 6.982

9.  Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation.

Authors:  Yichuan Xiao; Jin Jin; Mikyoung Chang; Jae-Hoon Chang; Hongbo Hu; Xiaofei Zhou; George C Brittain; Christine Stansberg; Øivind Torkildsen; Xiaodong Wang; Robert Brink; Xuhong Cheng; Shao-Cong Sun
Journal:  Nat Med       Date:  2013-04-21       Impact factor: 53.440

10.  A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4+ CD25high FOXP3+ Regulatory T Cells in Myelin-Specific TCR Transgenic Mice Contingent Upon Low-Efficiency T Cell Antigen Receptor Recognition.

Authors:  Cody D Moorman; Alan D Curtis; Alexander G Bastian; Sarah E Elliott; Mark D Mannie
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.